3.23
前日終値:
$3.20
開ける:
$3.21
24時間の取引高:
429.02K
Relative Volume:
0.61
時価総額:
$320.35M
収益:
$69.56M
当期純損益:
$-240.05M
株価収益率:
-1.0949
EPS:
-2.95
ネットキャッシュフロー:
$-121.90M
1週間 パフォーマンス:
+3.86%
1か月 パフォーマンス:
+13.33%
6か月 パフォーマンス:
+82.49%
1年 パフォーマンス:
-13.40%
Adc Therapeutics Sa Stock (ADCT) Company Profile
ADCT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ADCT
Adc Therapeutics Sa
|
3.23 | 359.23M | 69.56M | -240.05M | -121.90M | -2.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-08 | 開始されました | Stephens | Overweight |
2024-05-30 | 開始されました | Cantor Fitzgerald | Overweight |
2024-03-28 | 開始されました | Guggenheim | Buy |
2023-08-10 | アップグレード | JP Morgan | Underweight → Neutral |
2023-04-24 | ダウングレード | BofA Securities | Neutral → Underperform |
2022-12-06 | 開始されました | CapitalOne | Overweight |
2022-11-09 | ダウングレード | BofA Securities | Buy → Neutral |
2022-09-21 | 開始されました | JP Morgan | Overweight |
2022-09-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2021-11-09 | 開始されました | Wolfe Research | Outperform |
2021-08-17 | 再開されました | Jefferies | Buy |
2021-08-09 | 開始されました | RBC Capital Mkts | Outperform |
2021-06-15 | 開始されました | Cantor Fitzgerald | Overweight |
2020-12-03 | 開始されました | Stifel | Hold |
2020-10-29 | 開始されました | H.C. Wainwright | Buy |
2020-06-09 | 開始されました | BofA/Merrill | Buy |
2020-06-09 | 開始されました | Cowen | Outperform |
すべてを表示
Adc Therapeutics Sa (ADCT) 最新ニュース
Is ADC Therapeutics SA a good long term investmentAccelerated wealth building - Autocar Professional
What drives ADC Therapeutics SA stock priceBreakout stock performance - jammulinksnews.com
What analysts say about ADC Therapeutics SA stockOutstanding risk-reward balance - jammulinksnews.com
ADC Therapeutics SA Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment - TipRanks
What makes ADC Therapeutics SA stock price move sharplyCapital Growth Picks - Newser
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Market Sentiment Analysis - Newser
How ADC Therapeutics SA stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2%What's Next? - MarketBeat
Adc Therapeutics Sa shares fall 1.88% after-hours as Sonnet Biotherapeutics, Inc. announces $888 million funding. - AInvest
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2% – Here’s Why - Defense World
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics (ADCT) Files Prospectus for Share Sale - GuruFocus
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? - Weekly Voice
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
ADC Therapeutics (ADCT) Price Target Lowered by RBC Capital | AD - GuruFocus
ADC Therapeutics price target lowered to $5 at RBC on growth outlook - Investing.com
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
Guggenheim Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim - MarketBeat
Adc Therapeutics Sa (ADCT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):